Invivyd (IVVD) Common Equity (2020 - 2026)
Invivyd's (IVVD) quarterly Common Equity came in at $181.1 million in Q2 2026, up 323.19% on a YoY basis from $42.8 million in Q2 2025, and down 25.03% quarter-over-quarter from $241.5 million in Q4 2025.
Analysis
Invivyd (IVVD) Common Equity (2020 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Common Equity for 7 consecutive years, with $181.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Common Equity rose 323.19% year-over-year to $181.1 million; the trailing twelve-month figure through Jun 2026 stood at $181.1 million (up 323.19% YoY), and the FY2025 full-year result was $241.5 million, up 257.63% from the prior year.
- Common Equity retreated to $181.1 million in Q2 2026 per IVVD's latest filing, from $241.5 million in the prior quarter.
- Across five years, Common Equity topped out at $459.4 million in Q1 2022 and bottomed at $42.8 million in Q2 2025.
- Historically, Common Equity has averaged $219.0 million across 5 years, with a median of $181.1 million in 2026.
- The sharpest annual moves came in 2022 and 2025: Common Equity soared 544.45% in 2022, then sank 69.66% in 2025.
- Over 5 years, Common Equity stood at $356.0 million in 2022, then sank by 50.15% to $177.5 million in 2023, then slumped by 61.94% to $67.5 million in 2024, then soared by 257.63% to $241.5 million in 2025, then slipped by 25.03% to $181.1 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $181.1 million, $241.5 million, and $93.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 181.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 181.08 Mn |
| Dec 31, 2025 | 241.54 Mn |
| Sep 30, 2025 | 93.07 Mn |
| Jun 30, 2025 | 42.79 Mn |
| Mar 31, 2025 | 54.15 Mn |
| Dec 31, 2024 | 67.54 Mn |
| Sep 30, 2024 | 83.16 Mn |
| Jun 30, 2024 | 140.64 Mn |
| Mar 31, 2024 | 178.50 Mn |
| Dec 31, 2023 | 177.47 Mn |
| Sep 30, 2023 | 246.50 Mn |
| Jun 30, 2023 | 281.56 Mn |
| Mar 31, 2023 | 326.75 Mn |
| Dec 31, 2022 | 355.97 Mn |
| Sep 30, 2022 | 377.44 Mn |
| Jun 30, 2022 | 414.84 Mn |
| Mar 31, 2022 | 459.39 Mn |
| Dec 31, 2021 | 558.02 Mn |
| Sep 30, 2021 | 633.21 Mn |
| Jun 30, 2021 | -144.62 Mn |